Behnam Sadeghi1, Yaser Heshmati2, Bita Khoein3, Helen Kaipe3, Mehmet Uzunel3, Julian Walfridsson2, Olle Ringdén4. 1. Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet and Karolinska University Hospital Huddinge, Stockholm, Sweden. Electronic address: behnam.sadeghi@ki.se. 2. Center for Hematology and Regenerative Medicine (HERM), Department of Medicine, Karolinska Institutet and Karolinska University Hospital Huddinge, Stockholm, Sweden. 3. Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet and Karolinska University Hospital Huddinge, Stockholm, Sweden. 4. Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet and Karolinska University Hospital Huddinge, Stockholm, Sweden; Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet and Karolinska University Hospital Huddinge, Stockholm, Sweden.
Abstract
BACKGROUND AIMS: Human decidual stromal cells (hDSCs) may cure acute graft-versus-host disease (GVHD) in humans. We evaluated immunosuppression by xenogenic hDSCs in mice, both in vitro and in vivo. METHODS: hDSCs inhibited mouse lymphocyte proliferation in allo- and xeno-stimulation assays in mixed lymphocyte culture (MLC) and after mitogenic stimulation. The immunosuppressive effect of hDSCs was dose-dependent and strain-independent. Trans-well experiments showed that hDSCs needed cell-to-cell contact to be immunosuppressive. In a GVHD model, Balb/c mice were transplanted with bone marrow and splenocytes from C57BL/6 a donor. Varying doses of hDSCs (10(5)-10(6) per mouse) were infused at different time points. Recipient mice showed lower GVHD scores than untreated mice, but they did not have consistently improved survival. Histopathological investigation of liver, gastrointestinal tract and skin of animals with GVHD did not show any significant improvement from hDSC infusion. RESULTS: hDSCs were transduced with immunosuppressive genes including those encoding interleukin-10, prostaglandin-E2 receptor, indoleamine dioxygenase, interferon-γ and programmed death ligand-1. Transduced and untransduced hDSCs showed similar effects in vitro and in vivo. At a dose of 10(6)hDSCs per mouse, the majority of recipients died of embolism. CONCLUSIONS: hDSCs inhibit allo-reactivity, xeno-reactivity and mitogen-induced stimulation in mouse lymphocytes. Although the GVHD score was reduced by hDSC infusion, survival and GVHD histopathology were not improved. One reason for failure was fatal embolism.
BACKGROUND AIMS: Human decidual stromal cells (hDSCs) may cure acute graft-versus-host disease (GVHD) in humans. We evaluated immunosuppression by xenogenic hDSCs in mice, both in vitro and in vivo. METHODS: hDSCs inhibited mouse lymphocyte proliferation in allo- and xeno-stimulation assays in mixed lymphocyte culture (MLC) and after mitogenic stimulation. The immunosuppressive effect of hDSCs was dose-dependent and strain-independent. Trans-well experiments showed that hDSCs needed cell-to-cell contact to be immunosuppressive. In a GVHD model, Balb/c mice were transplanted with bone marrow and splenocytes from C57BL/6 a donor. Varying doses of hDSCs (10(5)-10(6) per mouse) were infused at different time points. Recipient mice showed lower GVHD scores than untreated mice, but they did not have consistently improved survival. Histopathological investigation of liver, gastrointestinal tract and skin of animals with GVHD did not show any significant improvement from hDSC infusion. RESULTS: hDSCs were transduced with immunosuppressive genes including those encoding interleukin-10, prostaglandin-E2 receptor, indoleamine dioxygenase, interferon-γ and programmed death ligand-1. Transduced and untransduced hDSCs showed similar effects in vitro and in vivo. At a dose of 10(6)hDSCs per mouse, the majority of recipients died of embolism. CONCLUSIONS: hDSCs inhibit allo-reactivity, xeno-reactivity and mitogen-induced stimulation in mouse lymphocytes. Although the GVHD score was reduced by hDSC infusion, survival and GVHD histopathology were not improved. One reason for failure was fatal embolism.
Authors: Alison J Eastman; Erin N Vrana; Maria T Grimaldo; Amanda D Jones; Lisa M Rogers; Donald J Alcendor; David M Aronoff Journal: Am J Reprod Immunol Date: 2020-10-16 Impact factor: 3.886
Authors: Raquel Muñoz-Fernández; Claudia De La Mata; Francisco Requena; Francisco Martín; Pablo Fernandez-Rubio; Tatiana Llorca; Maria José Ruiz-Magaña; Carmen Ruiz-Ruiz; Enrique G Olivares Journal: Stem Cell Res Ther Date: 2019-06-14 Impact factor: 6.832
Authors: Yaser Heshmati; Shabnam Kharazi; Gözde Türköz; David Chang; Esmat Kamali Dolatabadi; Johan Boström; Aleksandra Krstic; Theodora Boukoura; Emma Wagner; Nadir Kadri; Robert Månsson; Mikael Altun; Hong Qian; Julian Walfridsson Journal: Sci Rep Date: 2018-07-25 Impact factor: 4.379